Lon Cardon - 29 May 2026 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)

Reporting relationship: Director
Issuer ticker: MIRM
Reported as of: 29 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Jun 2026, 19:50:09 UTC
Prior SEC filing: 02 Jun 2025
Next SEC filing: 17 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Judit Ryvkin, Attorney-in-Fact

Key filing fact

Lon Cardon filed Form 4 for Mirum Pharmaceuticals, Inc. (MIRM) on 02 Jun 2026.

Key facts

This page summarizes Lon Cardon's Form 4 filing for Mirum Pharmaceuticals, Inc. (MIRM).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 02 Jun 2026, 19:50.

Change

Previous filing in this sequence was filed on 02 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001854337 Primary reporting owner

Cardon Lon

Relationship: Director
Address: C/O MIRUM PHARMACEUTICALS, INC., 989 E HILLSDALE BLVD., SUITE 300, FOSTER CITY
Signature: /s/ Judit Ryvkin, Attorney-in-Fact
Signature date: 02 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MIRM transaction

Common Stock

Options Exercise

Transaction value
Shares: +3,977
Change %: +70%
Price
Shares after: 9,680
Date: 29 May 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MIRM transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -3,977
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 29 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,977
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer).

Footnote F2

Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests on May 29, 2026.